RNActive® prophylactic vaccines represent a novel technology for the production of safe, efficacious and cost-effective vaccines for infectious diseases.
In March 2014, CureVac received the EUR 2 million Vaccine Prize from the European Commission for its RNActive® vaccine technology. In particular, the jury acknowledged the fact that the mRNA-based vaccines do not require a cold chain during transport and storage. Therefore, this novel technology may enable the transportation of life-saving vaccines to people worldwide in safe and affordable ways. Through the use of CureVac’s technology, it is possible to rapidly produce mRNA-based vaccines against infectious diseases and to deliver these to the most remote areas of the world without requiring a cold chain.
Upon vaccination, the prophylactic RNActive® vaccines are taken up by different cells. The antigen-presenting cells (APCs) express the corresponding antigens and present these to both CD4+ helper T-cells and CD8+ cytotoxic T-cells. Prophylactic RNActive® vaccines elicit antibody- and T-cell-dependent protection.
Importantly, RNActive® vaccines can be produced easily and quickly and match any sequence provided.